In fact, a recent clinical study on renal cancer and melanoma utilizing a DNA methylation inhibitor along with high-dose interleukin-2 achieved encouraging response rates attributed to facilitation of the immune response against the tumor [65]. Here, IL2 is linked to melanoma.